Developing innovative biologic therapeutics with transformative clinical potential. (NASDAQ: VERA)

Committed to the treatment of endocrine-related diseases.

Focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. (NASDAQ: AVTE)

Developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness thepower of the innate immune system to treat cancer. (NASDAQ: BOLT)

A drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. (NASDAQ: ATHA)

Developing cures for cancer through drugs that alter the body’s first line of defense, innate immunity.

Developing novel and innovative therapeutic strategies for NASH and other metabolic, inflammatory and fibrotic diseases.

Promedior is a clinical-stage biotechnology company pioneering the development of Pentraxin-2 therapeutics to treat diseases involving fibrosis. (Acquired by Roche)

Developing compounds to selectively modulate mTORC1 that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.

Targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders. (NASDAQ: KRTX) (Acquired by Bristol Myers Squibb)

CinCor’s mission is to advance promising clinical candidates toward marketing approval; focusing on cardiovascular, metabolic and kidney diseases. (NASDAQ: CINC) (Acquired by AstraZeneca)

Inozyme Pharma is a biotechnology company developing new medicines to treat rare, debilitating, and life-threatening calcification disorders for which there are no adequate treatment options. (NASDAQ: INZY)

Quanta is an early-stage biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes.

XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.

Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. (NASDAQ: KNSA)

Neurana Pharmaceuticals is a privately held clinical stage specialty pharmaceutical company developing a novel treatment for acute muscle spasms.

VelosBio is a pre-clinical company focused on developing next-generation antibody drug conjugate (ADC) therapies to novel targets in oncology indications of high unmet need. (Acquired by Merck)

Akouos is a biotechnology company developing novel gene therapies for the treatment of monogenic hearing disorders. (NASDAQ: AKUS) (Acquired by Lilly)

Y-mAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer. (NASDAQ: YMAB)

Pionyr Immunotherapeutics, Inc. develops antibody therapeutics that increase the body’s antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment. (Acquired by Gilead)

Medeor Therapeutics is a private, late clinical stage, biotechnology company dedicated to the discovery, development, and commercialization of transformative and personalized cellular immunotherapies.

Developing transformative therapies for patient use in the first moments of acute cardiovascular symptoms.

Treating chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular, atopic dermatitis and psoriasis. (Acquired by Novartis)

Treating diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. (NASDAQ: MCRB)

A biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs. (NASDAQ: NXTC)

A clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. (NASDAQ: MRUS)

Treating serious infections resulting from multi-drug resistant bacteria. (NASDAQ: ITRM)

Antibacterials to treat serious drug-resistant bacterial infections. (NASDAQ: ETTX)

Hospital-based therapies for the management of acute, life-threatening neurological conditions. (NASDAQ: EDGE)

Topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options.

A biopharmaceutical company focused on the development of specialty drugs.

Developing an oral drug candidate for acromegaly. (NASDAQ: CHMA)

Developing a novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells. (NASDAQ: CMPI) (Acquired by Regeneron)

Developing biologics for medical conditions where there has been no approved or satisfactory therapy.

New treatments for people with serious, rare diseases through the application of gene therapy technology. (NASDAQ: BOLD) (Acquired by Astellas)

Focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. (NASDAQ: LIFE)

Developing differentiated prodrug versions of high-value protein drugs, such as growth hormone. (NASDAQ: ASND)

Development of novel therapeutic compounds for autoimmune and inflammatory diseases. (NASDAQ: APLS)

Dramatically improving health outcomes for patients suffering from diseases caused by HPV and other viruses.

Developing broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to Candida, Aspergillus and rare molds. (Acquired by Pfizer)

Focused on the treatment of kidney and liver diseases including hyperkalemia. (Acquired by AstraZeneca)

Therapeutics for the treatment of endocrine disorders, including human growth hormones. (NASDAQ: VSAR)

Developing cancer therapeutics and oncology supportive care products that are safer and more effective than existing treatments.  (Acquired by GlaxoSmithKline)

Focused on developing curative, one-time gene therapy products including lead gene therapy candidate, for RPE65-related blindness. (NASDAQ: ONCE) (Acquired by Roche)

Developing innovative products for the treatment of urological diseases.

Therapeutics targeting dry eye disease. (Acquired by Shire)

Leading specialty pharmacy offering medication and clinical services to patients with chronic conditions. (Acquired by Catamaran)

Advancing and developing novel antibodies for a broad range of diseases involving protein misfolding or cell adhesion, including amyloidosis. (NASDAQ: PRTA)

Focused on discovering and developing first-in-class small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe. (NASDAQ: PRNB) (Acquired by Sanofi)

Specializing in the development of novel therapeutics to treat diseases of the eye. (NASDAQ: OPHT)

Dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labor. (NASDAQ: OBSV)

Significantly improving treatment outcomes for patients with cancer by applying its proprietary ProTide technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. (NASDAQ: NCNA)

Develops and commercializes non-invasive methods for analyzing DNA. (NASDAQ: NTRA)

Developing tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. (NASDAQ: SYBX)

Focused on treatments for chronic and episodic migraines. (Acquired by TEVA)

A range of pharmaceutical products and medical devices using proprietary collagen-based technologies. (Acquired by Gurnet Point)

Combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. (NASDAQ: HSGX)

Comprehensive portfolio of OTC pharmaceutical products in liquid ‘shot’ format.

Developing and commercializing transformative therapeutics for treating Parkinson’s disease. (ACQR, Acquired by Acorda Therapeutics)

Prevention or treatment of inner ear disorders, for acute inner ear tinnitus and for acute inner ear hearing loss. (NASDAQ: EARS)

Specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. (NASDAQ: ALIM)

Specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. (NASDAQ: ACRS)

Treatment for skin redness associated with rosacea, actinic solar purpura and peri-procedural bruising of the skin. (Acquired by Allergan)

Antibiotics for gram-positive bacterial infections, including those caused by MRSA. (Acquired by Cubist)

Focused on innovative products addressing significant benign gynecological conditions and infertility. (Acquired by Gideon Richter)

Small molecule oncology drugs targeting the pi3Kinase/ mTor pathway. (Acquired by Takeda)

Addressing critical unmet needs in the areas of gastroenterology and hepatology. (NADSAQ: HPTX) (Acquired Horizon Therapeutics)

Development of breakthrough drugs targeting the oxygen metabolic pathways. (NASDAQ: GRTX)

A developer of high-quality therapeutics with a robust pipeline of biosimilar products. (NASDAQ: CHRS)

Advancing a C-peptide replacement therapy for treating diabetes-related microvascular problems.

Drugs for the treatment of cancer and infectious diseases.

Leveraging the therapeutic benefits of essential fatty acids in treating cardiovascular disease. (NASDAQ: AMRN)

Dedicated to the discovery and development of novel treatments for glaucoma. (NASDAQ: AERI)

Focused on the treatment of obesity. (NASDAQ: OREX)

Focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases. (Acquired by Malllinckrodt Pharmaceuticals)

Therapeutics approved for the treatment of pediatric ADHD. (Acquired by Pfizer)

Development of Resolor for the symptomatic treatment of chronic constipation. (MOVE, Acquired by Shire)

Dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders including epilepsy. (NASDAQ: MRNS)

Novel therapeutic antibodies for cancer and autoimmune diseases. (Acquired by MedImmune)

Creating novel catalytic biopharmaceutical products based on engineered human proteases.

Focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. (NASDAQ: ANTH)

Develop therapeutic agents that selectively target tumor cells for the treatment of cancer. (Merged with Molecular Templates)

Saegis Pharmaceuticals, Inc., a development-stage company, engages in the discovery, development, and licensing of drugs to address behavioral disorders.

Developing drugs for chronic disorders of the central nervous system, such as chorea associated with Huntington’s disease. (Acquired by Biovail)

Drugs for pulmonary diseases, including Ventavis for pulmonary arterial hypertension. (COTX, Acquired by Actelion)

Development and commercialization of novel pharmaceutical products for pain management.

Developing antibodies and antigens (ADC’s) for the treatment of cancer. (NASDAQ: SGEN)

PharmaSonics, Inc. is a developer of therapeutic ultrasound catheter-based technology.

Products for antibiotic-resistant infectious diseases, including Esbriet for idiopathic pulmonary fibrosis. (Acquired by Roche)

Focusing on the discovery, development, and commercialization of innovative treatments to serve unmet medical needs. (SWX: ATLN)